Bowel Cancer and Biomarker Research Lab

Bowel cancer, also known as colorectal cancer, is the second most common cancer in Australian men and women. It affects 1 in 13 people. It is also Australia’s second deadliest cancer, with over 5,000 people dying each year. Early detection through screening can improve survival rates, however further research is needed to help find cures and prevent the disease.

The Bowel Cancer and Biomarker Laboratory at the Kolling Institute uses advanced technologies to study the genes and proteins responsible for bowel cancers growing and spreading. Our aim is to use a patient’s own molecular information to understand the risk of bowel cancer developing and to guide treatment options. As part of our research, we are studying how to control bowel polyp growth, which are precursors to cancer. We are doing this through diet and chemotherapy drugs.

Mark-P-Molloy Prof Mark P. Molloy, PhD | Lawrence Penn Chair of Bowel Cancer Research

The University of Sydney | Northern Clinical School
Faculty of Medicine and Health
Honorary Professor | Dept. Molecular Sciences, Macquarie University
Secretary | Australasian Proteomics Society

Dr Jun Li PhD

Postdoctoral Research Fellow

Dr Binh Pham, PhD

Postdoctoral Scientist

Dr Benita Tse

Postdoctoral Scientist

Matthew McKay - Senior Research Officer

Bharat Venkatesh Gunappa - Research Officer

Lydia Beaton - MD Research Project Student

Current bowel cancer research focuses on:

  • Why and how some bowel polyps become cancers
  • Which bowel tumours are likely to spread
  • Molecular make-up of colorectal tumours
  • Early detection of disease recurrence

Our research is facilitated by specimens from clinical projects we run including:

  • Sydney 1000 bowel cancer study
  • IMAP Bowel polyp study

Events, News and Seminars

The Kolling’s up and coming talent recognised

The Kolling’s up and coming talent recognised

Acting Executive Director Professor Jim Elliott has announced the winners of the inaugural Kolling I..... Read more

Category: Awards

First Australian imaging technology to deliver research windfall

First Australian imaging technology to deliver research windfall

An exciting project between the University of Sydney and the Northern Sydney Local Health District ..... Read more

Category: World-leading technology

Cancer expertise recognised

Cancer expertise recognised

The Kolling’s Dr Amanda Hudson will lead an exciting pilot study after being awarded an innovation g..... Read more

Category: Funding support, Neuroscience and Pain Research